| Popis: |
Arnica montana L., like many endangered species, does not give stable yields in commercial plantations. Other Arnica species were investigated for their pharmaceutical activity and A. chamissonis Less., was confirmed as a pharmaceutical substitute for A. montana, extracts having on average 40% higher inhibition of lipoxygenase activity and reduction of superoxide and hydroxyl free radicles on a tissue dry weight basis. A micropropagation protocol was established for A. chammisonis and a plantation of 10,050 plants was established with 0.9% microplant loss at the weaning stage. The plantation is now in commercial production. |
Full text from SpringerLink